Commit Biologics ApS, a developer of new drugs for cancer and autoimmune diseases, has formed a scientific advisory board with experts in drug development and immunology. The board will be co-chaired by Janine Schuurman, an antibody expert and former Genmab executive, and Commit's CEO Mikkel Wandahl Pedersen. They will be joined by four members: Paul Parren, a professor of molecular immunology and biotech entrepreneur; Gavin Thurston, an R&D executive and former senior vice president of oncology research at Regeneron; Susan Kalled, an immunologist and formerly chief scientific officer at Dianthus Therapeutics and Compass Therapeutics; and Esper Boel, a molecular biologist and former senior executive at Novo Nordisk.
Copyright 2025 Evernow Publishing Ltd